Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6376287 | 0.84 | PTGS1 (0.56) | ACHECYP3A4LMNAPARP1MEN1 | |
| SCHEMBL289959 | 0.84 | CYP3A4 (0.49) | ACHECYP3A4LMNAPARP1MTNR1A | |
| SCHEMBL21225979 | 0.81 | ALOX5 (0.57) | ACHECYP3A4LMNAPARP1MTNR1A | |
| SCHEMBL715536 | 0.81 | CYP3A4 (0.56) | ACHECYP3A4LMNAPARP1CNR2 | |
| SCHEMBL1561685 | 0.81 | CYP3A4 (0.56) | ACHECYP3A4LMNAPARP1MTNR1A | |
| SCHEMBL9132980 | 0.81 | THRB (0.54) | ACHECYP3A4LMNAMEN1KMT2A | |
| SCHEMBL4449661 | 0.81 | PPARA (0.55) | ACHEPPARA | |
| SCHEMBL26430086 | 0.81 | PPARA (0.55) | ACHEPPARA | |
| SCHEMBL11857369 | 0.80 | ACHE (0.46) | ACHECYP3A4LMNAPARP1MTNR1A | |
| SCHEMBL13314605 | 0.80 | ALDH1A1 (0.55) | ACHECYP3A4LMNAPARP1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2984055-B1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9758445-B2 | Preparation of surfactants via cross-metathesis | MATERIA, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9663459-B2 | Preparation of surfactants via cross-metathesis | MATERIA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160145204-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. | 2016-05-26 | — | — | US | disclosed |
| EP-2984055-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | Materia, Inc. (US) | 2016-02-17 | — | — | EP | disclosed |
| WO-2015126462-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| WO-2014169080-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | SMURF2, EPHX2, SMURF1 | ACHE 2620/4885CYP3A4 398/4885LMNA 1872/4885 |
| US-20160145204-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | SMURF2, SMURF1, ABCB4 | ACHE 3166/4885CYP3A4 915/4885LMNA 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.